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Abstract
The glucose-phosphorylating enzyme glucokinase, a promising target for developing new antidiabetic
agents, was identified through the combined efforts of basic research and human biochemical
genetics. Allosteric glucokinase activators (GKAs) were discovered by high-throughput screening of a
large compound library and first reported in 2003. GKAs stimulate insulin release and glucose
metabolism in the liver thereby lowering blood sugar, and promising trials in humans demonstrate
that they are highly effective in patients with type 2 diabetes mellitus. Many companies are now
attempting to develop effective and safe GKAs for treating diabetics.
Introduction and context
Selecting new targets for developing antidiabetic drugs
for type 2 diabetes mellitus (T2DM) is best guided by
considerations of established physiological chemistry of
glucose homeostasis and of prevailing views about
T2DM pathophysiology because the disease genetics
that could serve as another guiding principle remain
prohibitively perplexing. The glucose-phosphorylating
enzyme glucokinase (GK) (also called hexokinase IV or
D) was identified as an outstanding drug target for
developing antidiabetic medicines because it has an
exceptionally high impact on glucose homeostasis,
serving as a glucose sensor of the pancreatic beta cell
and as a rate-controlling enzyme for hepatic glucose
clearance and glycogen synthesis, both processes that
are impaired in T2DM [1]. In the mid-1990s, high-
throughput screening of 120,000 small molecules of the
Roche (Basel, Switzerland) compound library, using a
screening assay based on measuring the effect on
recombinant GK inhibited by GK regulatory protein
(GKRP), identified a lead molecule that stimulated GK
directly but also blocked GKRP inhibition of the enzyme
[2]. The optimization effort of this newly discovered
GK activator (GKA) molecule resulted in the discovery of
more potent, preclinically effective, and apparently safe
compounds and culminated in the development of
piragliatin (Figure 1), which was advanced to phase II
human trials but then shelved for undisclosed reasons
[2-6]. The first 2003 report in Science [2] on the
development and successful preclinical use of GKAs
was soon followed by the issuance of more than 100
patents for GKAs of different chemical structure, demon-
strating the keen interest of the pharmaceutical industry
in this new class of antidiabetics [7-10]. The report led to
the publication of a flood of studies in animal models
and the first human trials, contributing significantly to
the proof of principle for GKA use as a novel treatment
for this disease [1,3,7-10].
Recent advances
The role of GK in glucose homeostasis
To comprehend the mechanism of action of GKAs and
the rationale of using them for treating diabetics, the role
of GK at the molecular, cellular, organ, and whole-body
levels has to be understood [1,11,12]. GK is unique
among hexokinase isoenzymes. It is a monomer with a
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(i.e., the half-saturation concentration) is about 7.0 mM,
and the co-substrate MgATP saturates physiologically
(Km = 0.4 mM). The enzyme shows sigmoidal glucose
dependency (has a Hill number of 1.7) and thus is most
sensitive to glucose change in the 4.0-mM range. The
crystal structure of GK has been solved [13], both as a
ligand-free apoenzyme in a ‘super-open’ conformation
and as a ternary complex with one D-glucose and a
GKA bound in a ‘closed’ conformation (Figure 2). An
intermediate so-called ‘open’ conformation has been
postulated to exist. There is strong evidence that the
transition between super-open and closed forms is slow
compared with the rate of the catalytic cycle, and this
evidence is used to explain the physiologically important
cooperativity with regard to glucose. Cellular expression
of GK is governed by a single gene with two promoters,
one of these operating constitutively in GK-containing
glucose-sensing endocrine cells (most importantly, in
the pancreatic beta cell) and in neurons, and the other
controlling hepatic GK expression tightly regulated by
insulin. GK thus governs the beta-cell threshold for
glucose-stimulated insulin release (GSIR). It accom-
plishes this by operating in tandem with the adenine
nucleotide-sensitive K-channel/SUR1 (sulfonylurea
receptor-1) complex and L-type Ca-channels. Alterations
of any one of the three beta-cell components influence
the threshold for GSIR profoundly. The rate of glucose
metabolism as determined by blood glucose levels and
the beta-cell GK content is coupled to the two channels:
directly by the ATP/ADP ratio to the K-channels and
indirectly by the membrane potentialto the Ca-channels.
High glucose increases GK expression in beta-cells as
much as 5- to 10-fold, in a concentration-dependent
manner, and thus sensitizes them to glucose stimulation
of insulin biosynthesis and release. In excess of 99% of
the bodies’ GK protein resides in the liver, explaining its
critical role postprandially in the high-capacity clearance
of glucose from the blood stream coupled with enhanced
glycogen synthesis and glucose catabolism. In hepato-
cytes, GK is subtly regulated by GKRP, a 68-kDa
Figure 1. Chemical structures of glucokinase activators
Chemical structures of glucokinase activators used in extensive preclinical
studies using (a) RO-0274375-000 (Cpd A) or (b) RO-0281675-000
(Cpd R) and short-term phase II trials in type 2 diabetes mellitus with
(c) RO-4389620-000 (piragliatin) [1-6,8-10]. Cpd, compound.
Figure 2. Effect of glucose and glucokinase activator (GKA)
binding on the configuration of the allosteric activator site of
glucokinase (GK)
A critical cutout of the GK structure is presented to show the
conformational change induced by glucose allowing GKA to bind. Note the
marked rearrangement of known contact amino acids in the drug receptor
region of the enzyme. Based on structures reported by Kamata et al. [13].
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the sequestration of GK in the nucleus when glucose
levels are low [14]. High glucose and fructose-1-P
(a metabolite of dietary fructose) dissociate the GK/
GKRP complex, which results in reactivation and
relocation of GK to the cytosol. Hepatic GK regulates
glycogen metabolism, glycolysis, the pentose-P shunt,
glucose oxidation, and associated oxidative phosphor-
ylation and ATP production. GK influences hepatic lipid
metabolism and gluconeogenesis. The predominant role
of this core control system based on beta-cell and hepatic
GK is probably complemented in ways to be explored by
the function of other GK-containing cells in the
hypothalamus, the brain stem, the portal vein, entero-
endocrine K and L cells, pancreatic islet alpha cells as well
as gonadotropes and thyrotropes [1,11] (Figure 3).
GK status in T2DM
A drug receptor is therapeutically useful only if it is not
significantly impaired or deleted by the disease to be
treated [1,15,16]. What is the status of GK in T2DM? The
evidence is strong that beta-cell GK is functional in
T2DM, although total GK is probably diminished
because beta-cell mass and function are reduced as the
disease progresses [1,16]. The known right shift and the
blunting of the dose-dependency curve of GSIR in T2DM
are probably the result of multiple yet-to-be-defined
defects of the signaling chains controlling GSIR and
Figure 3. The network of glucokinase (GK)-containing tissues throughout the body and their connections
Expression of GK in the pancreatic islet alpha and beta cells, other endocrine cells (including pituitary cells), and cells in the portal vascular tree and central
nervous system (including the hypothalamus and brain stem) makes up about 0.1% of the body’s total GK complement. The liver produces the rest (about
99.9%). The pancreatic islet cells and the liver constitute the basic GK-dependent regulatory system maintaining glucose homeostasis. ANS, autonomic
nervous system; GKA, glucokinase activator. Modified from Matschinsky [1], Nat Rev Drug Discov 2009.
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content or activity of GK (or both). The situation of
hepatic GK is quite another matter [1,15]. Hepatic GK
expression is insulin-controlled and may be greatly
reduced in severe forms of T2DM as demonstrated in
human and animal models of the disease with severe
insulin deficiency. Still, whatever GK remains available
or is newly induced by GKA-stimulated insulin release is
probably responsive to activation by GKAs. Nothing is
known about the status of GK in other cells expressing
the enzyme but it is speculated that constitutive
expression of GK might be unaltered by the disease.
GKA action at the molecular, cellular, organ, and
whole-body levels
On theoretical grounds, pharmacological activation of
GK is expected to have a high potential for the treatment
of T2DM and perhaps also T1DM. Early results with
GKAs support this view. GKAs are, in general, small
molecules with a considerable variety of chemical
structures (selected examples in Figure 1) that mostly
adhere to a common pharmacophore model with related
structural motifs [1,3,7-10,12]. The model consists of a
center of a carbon or an aromatic ring with three
attachments to it. Two of these are hydrophobic, and at
least one of the two is aromatic. The third attachment is a
2-aminoheterocycle or N-acyl urea moiety that provides
the basis of forming an electron donor/acceptor interac-
tion with R63 of GK. At least a dozen other amino acids
have been shown to be involved in GKA binding: V62,
R63, S64, T65, G68, S69, G72, V91, W99, M210, I211,
Y214, Y215, M235, V452, V455, and K459. It is
noteworthy that mutations of many of these lead to
activation of GK and cause hyperinsulinemic hypogly-
cemia. GKAs increase the affinity of recombinant GK for
glucose by as much as 10-fold and may also augment the
Vmax (maximum velocity) moderately, perhaps as much
as twofold. The affinity for MgATP is increased when
tested at glucose levels below the glucose S0.5. Some
GKAs lower the Hill coefficient such that they render the
enzyme more hexokinase-like. The potency of known
GKAs varies considerably, with dissociation constant
values ranging from low nanomolars to low micromo-
lars. Most GKAs do not bind to GK in the absence of
glucose. GKAs potentiate the competitive glucose rever-
sal of GK inhibition by GKRP. Binding of GKRP and
GKAs to GK is mutually exclusive. Little is known about
GKA effects on the known interaction of GK with cellular
organelles (e.g., mitochondria or insulin granules) or
other macromolecules besides GKRP (e.g., the pro-
apoptotic BAD [Bcl-2-associated death promoter] pro-
tein [17,18] or the bifunctional enzyme that generates
and hydrolyzes fructose-2,6-bisphospate [19]). Impaired
formation of a GK/BAD complex proposed to associate
with mitochondria and to enhance glucose oxidation
may be significant for the molecular pathogenesis of the
functional beta-cell defect and apoptotic beta-cell loss
known to cause T2DM. It is tempting to hypothesize that
GKAs might remedy this defect. Indeed, as reported at
the 2009 International Diabetes Federation meeting in
Montreal (Matschinsky et al., unpublished data), studies
from our laboratory have demonstrated a marked
reduction of glucose-induced respiration in islets iso-
lated from T2DM organ donors and showed that this
metabolic defect was partially or fully remedied in acute
studies using the Hoffmann-La Roche GKA piragliatin.
Therefore, it is not unreasonable to explore whether
GKAs are anti-apoptotic in GK-containing cells. As we
showed in these studies with islets of Langerhans
isolated from the pancreas of rodents or of normal and
diabetic human tissue donors, GKAs potentiate glucose
stimulation of insulin release and enhance the permis-
sive action of glucose for other physiological stimuli,
including amino acids, fatty acids, acetylcholine, and
GLP-1 (glucagon-like peptide-1). GKAs markedly
potentiate glucose induction of islet GK expression. It
can be extrapolated that they increase glucose stimula-
tion of insulin biosynthesis. Studies with isolated rat
hepatocytes demonstrated that GKAs stimulate glycolysis
and glycogen synthesis and effectively dissociate the
nuclear GK/GKRP complex, thus activating glucose
phosphorylation [3,15,20].
In intact control animals and a wide variety of animal
models of T2DM, GKAs uniformly lowered blood glucose
andstimulatedinsulinrelease[1-3,7-10].Theyalsocurbed
hepatic glucose production in normal and diabetic rats. In
a long-term study with C57black6J mice, GKAs prevented
the development of diet-induced diabetes with little effect
on the weight gain of the animals [21]. Results of human
trials with normal or diabetic patients showed that GKAs
reduced blood glucose dose-dependently and increased
insulin secretion. The blood glucose-lowering potential of
GKAs in T2DM is compellingly illustrated by results of
trials with piragliatin from Roche in a 5.5-day multiple
ascending dose study [5,6,17] and a 1-day single ascend-
ing dose study with ARRY403 from Array BioPharma
(Boulder, CO, USA) [22]. Moderate hypoglycemia was
observed at the highest dosages.
Implications for clinical practice
The published results of treating T2DM patients with
GKAs for periods of up to 1 week demonstrate that these
agents lower blood glucose effectively in a dose-
dependent manner without medically significant side
actions except (not surprisingly) moderate hypoglycemia
at the higher doses. Thus, intensive research and
development have produced a class of powerful
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contrasting it to all other available pharmacotherapies,
including insulin. It remains to be seen whether this
novelclass ofdrugwithstands the test oftimeand secures
for itself a significant place among approved antidiabetic
medicines. The massive current effort of at least 15
pharmaceutical companies to develop GKAs shows that
expectations for success in this endeavor are high. Of
remaining concern are the dangers of hypoglycemia, fatty
liver, and hyperlipidemia. Available results of preclinical
and clinicalstudies are, however, reassuring in this regard
and it is reasonable to argue that such potential side
effects can be managed by designing GKAs, which are less
potent than the currently known prototypes, or by
judicious dose regimens. All indications are that several
GKAs now in development will be advanced to phase II
and III trials [1-10]. Beyond their potential medical
significance, GKAs will also prove highly useful as an
experimental tool in studies of the GK molecule and of
glucose homeostasis in health and disease (Figure 3).
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